InflaRx N.V. (NASDAQ: IFRX) experienced a notable increase in short interest during December 2023. As of December 15, the company reported short interest of 2,745,086 shares, marking an increase of 26.7% from the previous month’s total of 2,166,680 shares. This change indicates that approximately 4.9% of InflaRx shares are currently sold short, reflecting growing bearish sentiment among investors. With an average trading volume of 847,910 shares, the days-to-cover ratio stands at 3.2 days.
Analysts Adjust Ratings on InflaRx Stock
Recent evaluations from several research analysts have impacted the stock’s outlook. On December 3, Leerink Partners lowered its rating from “strong-buy” to “hold.” Weiss Ratings reaffirmed a “sell (D-)” rating in a report issued on December 4. Conversely, HC Wainwright maintained a “buy” rating and set a price target of $6.00 for InflaRx shares. Additionally, Wall Street Zen downgraded the stock from “hold” to “sell” on November 8, while Raymond James Financial reiterated an “outperform” rating on December 5.
The consensus among five analysts currently stands at a “Moderate Buy” with an average price target of $7.50, according to data from MarketBeat.com. This mixed outlook may reflect the uncertainties surrounding the company’s financial performance and market positioning.
Financial Performance and Institutional Investments
InflaRx reported its latest earnings results on November 10, revealing an earnings per share (EPS) of ($0.16), consistent with analysts’ expectations. The company generated revenue of $0.03 million for the quarter, again matching forecasts. Analysts project that InflaRx will post an EPS of -$1.04 for the current fiscal year, indicating ongoing challenges in achieving profitability.
Institutional investors have shown varied interest in InflaRx shares recently. Bank of America Corp DE acquired a new position valued at approximately $3.3 million during the third quarter. Woodline Partners LP also purchased shares worth about $766,000 during the first quarter. 683 Capital Management LLC increased its stake by 26.8%, now holding 2,625,000 shares valued at $2.68 million after acquiring an additional 555,000 shares. Other notable transactions include Adage Capital Partners GP L.L.C. and ADAR1 Capital Management LLC, who made smaller investments in the biopharmaceutical company.
Currently, institutional investors hold around 42.39% of InflaRx’s stock, indicating a solid level of interest from larger market participants.
InflaRx N.V. is a clinical-stage biopharmaceutical company dedicated to discovering, developing, and commercializing therapies that target the complement system, particularly the C5a pathway. Its lead product candidate, vilobelimab (IFX-1), is a monoclonal antibody designed to selectively inhibit C5a, which plays a significant role in various autoimmune and inflammatory diseases. The company aims to meet high unmet medical needs by advancing treatments for conditions such as hidradenitis suppurativa and pyoderma gangrenosum, among others.
Vilobelimab has undergone multiple Phase II trials, demonstrating promising results in reducing key inflammatory markers and improving clinical outcomes. As InflaRx navigates its challenges, stakeholders will be watching closely for further developments in both its clinical trials and market performance.
